KellBenx Inc. is developing prenatal diagnostics that it says will capture larger amounts of intact fetal DNA from a maternal blood sample, allowing the biotech to diagnose a wider range of genetic abnormalities than marketed products that the company says capture only small fractions of poor quality genetic material.

KellBenx's prenatal diagnostic uses a mAb against an antigen located only the surface of nucleated fetal red blood cells to capture the cells for diagnostic applications.